Serologic response to <scp>mRNA COVID</scp>‐19 vaccination in lymphoma patients
Eric M. Jurgens(Memorial Sloan Kettering Cancer Center), Peter Martin(Northwestern University), Richard R. Furman(Cornell University), Silvia C. Formenti(Cornell University), Thomas J. Ketas(Cornell University), John P. Moore(Cornell University), Erik Francomano(NewYork–Presbyterian Hospital), John P. Leonard(New York University), Per Johan Klasse(Cornell University), Ashley Sukhu(NewYork–Presbyterian Hospital), Emeline Nguyenduy(NewYork–Presbyterian Hospital), Catherine B. Small(Cornell University), Erica B. Bhavsar(St James's University Hospital), Michael J. Satlin(Cornell University), A. Alberto González García(NewYork–Presbyterian Hospital), Zhen Zhao(Cornell University)
Cited by 27
Related Papers
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k